Turn a regulatory question into a bounded strategy brief

“What will FDA require?” is usually too broad to answer. The useful question names a product, indication, development stage, jurisdiction and choice that management must make.

Bound the authority

Regulatory analysis should distinguish statutes, regulations, final guidance, draft guidance, review precedent and commentary. Each carries different authority. FDA maintains a searchable collection of current guidance documents (FDA); the brief should preserve title, status, date, jurisdiction and retrieval time.

ARiDA’s regulatory lanes acquire and normalize the underlying material before synthesis. Citations point to the relevant authority, not to a generic agency homepage. Superseded text and draft status remain visible.

Separate text from strategy

The source may say that an endpoint is acceptable under stated conditions. It does not decide whether the company should fund the program. The strategy layer must connect the authority to the product context: target population, proposed claim, existing evidence, development plan and risk tolerance.

The Target Product Profile is a useful organizing device because it links desired labeling concepts to the evidence intended to support them (FDA). ARiDA can compare a minimal, base and aspirational profile, identify gaps against precedent and test whether the development plan supports the claimed differentiation.

Write the choice, not a legal essay

A decision brief should state the question, controlling authority, material facts, available paths, evidence gaps and recommended next action. It should also identify what requires agency interaction or qualified legal advice.

If the evidence is incomplete, the answer may be a meeting question, an assay requirement or a proposed study. That is more valuable than a confident prediction of agency behavior. The brief succeeds when management understands which facts are fixed, which interpretations are contestable and which action buys clarity.